- ►diabetesjournals.org RA DeFronzo, PR Fleck, CA Wilson, Q Mekki - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This double-blind, placebo-controlled, multicenter
study included 329 patients with poorly controlled diabetes randomized to
once-daily treatment with 12.5 mg alogliptin (n = 133), 25 mg alogliptin (n ... Cited by 11 - Related articles - All 3 versions
B Lee, L Shi, DB Kassel, T Asakawa, K … - European Journal of Pharmacology, 2008 - Elsevier The aim of the present research was to characterize the pharmacokinetic,
pharmacodynamic, and efficacy profiles of alogliptin, a novel
quinazolinone-based dipeptidyl peptidase-4 (DPP-4) inhibitor. Alogliptin ... Cited by 12 - Related articles - All 3 versions
- ►diabetesjournals.org [PDF] RA Defronzo, PR Fleck, CA Wilson, Q Mekki - Diabetes Care, 2008 - Am Diabetes Assoc *A full list of investigators is available in an online appendix at
http://care.diabetesjournals.org ... From the 1University of Texas Health
Science Center at San Antonio, San Antonio, Texas;and the 2Takeda Global ... Cited by 2 - Related articles - All 2 versions
P Covington, R Christopher, M Davenport, P … - Clinical therapeutics, 2008 - Elsevier Results: Of 56 enrolled patients (57% women; 93% white; mean age, 55.6 years;
mean weight, 89.8 kg; mean body mass index, 31.7 kg/m 2 ), 54 completed the
study. On day 14, the median T max was ~1 hour and the mean t 1/2 was 12.5 ... Cited by 30 - Related articles - All 3 versions
B Richter, E Bandeira-Echtler, K Bergerhoff, C … - Vascular Health and Risk Management, 2008 - pubmedcentral.nih.gov In type 2 diabetes mellitus (T2DM) there is a progressive loss of β-cell
function. One new approach yielding promising results is the use of the orally
active dipeptidyl peptidase-4 (DPP-4) inhibitors. However, every new ... Cited by 9 - Related articles - All 7 versions
J Green, M Feinglos - Vascular Health and Risk Management, 2008 - pubmedcentral.nih.gov Type 2 diabetes mellitus is an increasingly prevalent condition worldwide. The
complications of this disease are known to significantly increase the morbidity
and mortality of those affected, resulting in substantial direct and ... Cited by 3 - Related articles - All 7 versions
R Christopher, P Covington, M Davenport, P … - Clinical Therapeutics, 2008 - Elsevier Results: Thirty-six subjects (66 per cohort) were enrolled and completed the
study (29/36 [81% ] white; mean age, 26.6 years; mean weight, 76.00
kg)..Alogliptin was rapidly absorbed (median T max , 1-2 hours) and ... Cited by 17 - Related articles - All 2 versions
J Rosenstock, S Sankoh, JF List… - Diabetes Obes Metab, 2008 - interscience.wiley.com Correspondence to Julio Rosenstock, MD, Dallas Diabetes and Endocrine Center at
Medical City, 7777 Forest Lane, C-685, Dallas, TX 75230, USA. E-mail:
juliorosenstock@dallasdiabetes.com Disclosure summary: SS, PhD was ... Cited by 51 - Related articles - All 3 versions
D Bad, L im Harz, G Bad Lauterberg - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 5 - Related articles - All 3 versions
Y Moritoh, K Takeuchi, T Asakawa, O Kataoka … - European Journal of Pharmacology, 2009 - Elsevier The combination of two agents with different but complementary mechanisms of
action is a logical approach for treating patients with type 2 diabetes. Thus,
we evaluated chronic combination therapy with alogliptin, a highly ... Cited by 6 - Related articles - All 3 versions
